FDA approves HERNEXEOS for metastatic or unresectable non

Key takeaways:

The FDA approved Hernexeos for adults with unresectable or metastatic non-small cell lung cancer.

It received accelerated approval based on a 75% objective response rate in a Phase 1b trial.

The FDA approved Hernexeos (zongertinib tablets, Boehringer Engelheim) for the treatment of adults with unresectable or metastatic NSCLC, Boehringer Ingelheim announced in a press release.

Specifically, Hernexeos is indicated for patients whose tumors carry HER2 (ERBB2) tyrosine kinase domain activating mutations and who have previously received systemic treatment.

The FDA approved Hernexeos (zongertinib tablets, Boehringer Engelheim) for the treatment of adults with unresectable or metastatic NSCLC.

The FDA granted this indication under accelerated approval, based on data from the